Cargando…
Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
PURPOSE: Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that plays a major role in brain cholesterol homeostasis by converting cholesterol into 24S-hydroxycholesterol. The selective CH24H inhibitor soticlestat (TAK-935) is being pursued as a drug for treatment of seizures in developme...
Autores principales: | Koike, Tatsuki, Constantinescu, Cristian C., Ikeda, Shuhei, Nishi, Toshiya, Sunahara, Eiji, Miyamoto, Maki, Cole, Patricia, Barret, Olivier, Alagille, David, Papin, Caroline, Morley, Thomas, Fowles, Krista, Seibyl, John, Tamagnan, Gilles, Kuroita, Takanobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921165/ https://www.ncbi.nlm.nih.gov/pubmed/34651220 http://dx.doi.org/10.1007/s00259-021-05565-z |
Ejemplares similares
-
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
por: Nishi, Toshiya, et al.
Publicado: (2020) -
T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
por: Tamagnan, Gilles, et al.
Publicado: (2018) -
Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor
por: Nishi, Toshiya, et al.
Publicado: (2022) -
Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy
por: Constantinescu, Cristian C., et al.
Publicado: (2023) -
Preclinical properties and human
in vivo
assessment of
(123)
I-ABC577 as a novel SPECT agent for imaging amyloid-β
por: Maya, Yoshifumi, et al.
Publicado: (2016)